Most pathogens gain access to their host through mucosal surfaces. It is
therefore desirable to develop mucosal vaccines that elicit an immune response
to prevent this crucial first step in infection. Current mucosal vaccines are live
attenuated strains of pathogens. More recent efforts have focused on the use of
recombinant non-pathogenic gram-positive bacteria as live vaccine delivery
vectors. Here I have tested the potential of Lactococcus lactis to be used as a
vaccine vector. A recombinant strain of L. lactis has been constructed which
expresses and displays on its surface the C repeat region (CRR) of the M6
protein of Streptococcus pyogenes. I show that nasal vaccination of mice with
this strain elicited strong salivary IgA and serum lgG response. These responses
protected mice against a nasal challenge with S. pyogenes. Subcutaneous
vaccination with the same strain of L. lactis produced a strong serum lgG
response, but no salivary lgA response. Subcutaneous vaccination did not
protect the mice against nasal infections when the mice were challenged with
S. pyogenes. The immune response and protection afforded by concomitant
vaccination by both nasal and subcutaneous routes were better that that seen in
nasal vaccination alone. This study shows that an effective vaccine against
S. pyogenes is possible using L. lactis as a vaccine vector. It also opens up the
potential of L. lactis to be used in the development of vaccines to other mucosal
infections. / Graduation date: 2004
| Identifer | oai:union.ndltd.org:ORGSU/oai:ir.library.oregonstate.edu:1957/30816 |
| Date | 04 June 2003 |
| Creators | Mannam, Praveen |
| Contributors | Geller, Bruce L. |
| Source Sets | Oregon State University |
| Language | en_US |
| Detected Language | English |
| Type | Thesis/Dissertation |
Page generated in 0.0022 seconds